Racura Taps Beyond Drug Development for Key RC220 Lung Cancer Trial

An update from Race Oncology Ltd. ( (AU:RAC) ) is now available.

Racura Oncology has appointed Australian contract research organisation Beyond Drug Development to support its HARNESS-1 Phase 1a/b trial of RC220 in combination with osimertinib in patients with EGFR-mutated non-small cell lung cancer, with the study planned at five Australian sites and first patient recruitment targeted for the first quarter of calendar 2026, subject to governance approvals. The agreement, structured under a Master Service Agreement with an estimated value of $3.05 million based on enrolment of up to 80 patients, gives Racura access to Beyond’s flexible trial design and operational expertise, including advanced features such as circulating tumour DNA biomarkers, accelerated single-patient cohorts and a Bayesian Optimised Interval Design, marking a key operational milestone in bringing RC220 into the clinic and potentially strengthening Racura’s position in the competitive lung cancer treatment landscape.

More about Race Oncology Ltd.

Racura Oncology Ltd (ASX: RAC) is a Phase 3 clinical biopharmaceutical company focused on oncology, developing small molecule anticancer agents to address high unmet medical needs across multiple cancer indications. Its lead asset, RCDS1 (E,E-bisantrene), a MYC-targeting G4-DNA and RNA binding compound with a characterised safety profile, underpins proprietary formulation RC220, which is being advanced in Phase 3 acute myeloid leukaemia, a Phase 1a/b program in EGFR-mutant non-small cell lung cancer, and a Phase 1a/b combination program with doxorubicin aimed at delivering both cardioprotection and enhanced efficacy in solid tumours.

Average Trading Volume: 437,059

Technical Sentiment Signal: Strong Buy

Current Market Cap: A$489.9M

For an in-depth examination of RAC stock, go to TipRanks’ Overview page.